ABVC BioPharma, Inc. (ECOC) Return on equity 2020–2025
ABVC BioPharma, Inc. (ECOC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-71.2%FY2025 · since FY2020: -308.1% → -71.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -71.2% | +328.7 pp |
| FY2024 | -399.9% | +101.3 pp |
| FY2023 | -501.1% | +28.9 pp |
| FY2022 | -530.0% | -384.8 pp |
| FY2021 | -145.2% | +162.9 pp |
| FY2020 | -308.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ECOC financial trends
ECOC RevenueECOC Net incomeECOC Net marginECOC Gross profitECOC Gross marginECOC Operating incomeECOC Operating marginECOC Operating cash flowECOC Free cash flowECOC Capital expendituresECOC Stock buybacksECOC Dividends paidECOC Total assetsECOC Total liabilitiesECOC Shareholders’ equityECOC overview →